Affiliation:
1. Federal State Budgetary Institution «V.A. Almazov National Medical Research Centre» of the Ministry of Health of the Russian Federation.
Abstract
Aim:to estimate early and long-term outcomes in recipients under 18 years old who have been heart transplanted in Almazov National Medical Research Centre.Materials and methods. From April 2011 to September 2017 we performed 5 heart transplantations (HTx) in recipients under 18 years old (female) old) from adults donors. The median of age were 15 years (range 10–16 years), LVEF prior HTx – 17% (10–33%). Causes of heart failure were dilated cardiomyopathy (n = 2), non-compacted myocardium (n = 1), arrhythmogenic ventricular dysplasia (n = 1) and Ebstein’s anomaly (n = 1). They spent in HT waiting list 76 days (12–684 days). One patient underwent biventricular assist device Berlin Heart EXCOR implantation (days on support – 250) as a «bridge» to transplant. Due to coronary angiography (CAG) results 1 patient underwent HTx and CABG simultaneously. All recipients treated by triple-drug therapy (steroids, calcineurin inhibitors, mycophenolate mofetil), induction (thymoglobulin – n = 4, basiliximab – n = 1). We evaluated retrospectively laboratory-instrumental investigations and frequency of complications after HTx.Results.The median of survival after HT was 35,93 months (4,4–73,7 months), all of them are alive. Patients spent in ICU 12 days (4–18 days), but one – 18 days due to posterior reversible encephalopathy syndrome (PRES), tacrolimus was switched to cyclosporine. They required inotropic support during 3 days (3–8 days). In 1 yr after HT TTE results got to normal values, the same as VO2peak signifi cantly improved. According to EMB (n = 48) results there were no clinical signs of rejection, acute cellular rejection (R2) was diagnosed in 12,5% cases. In long-term follow-up there was no signifi cant post transplant complications and comorbidities.Conclusion.Pediatric heart transplantation is an effective treatment of terminal CHF. There was no signifi cant clinical rejection under combined immunosuppressive regimens. All patients recovered and went back to normal life. Physical capacity improved in all recipients.
Publisher
V.I. Shimakov Federal Research Center of Transplantology and Artificial Organs
Subject
Transplantation,Immunology and Allergy
Reference22 articles.
1. Mareev VYu, Fomin IV, Ageev FT, Arutyunov GP, Begrambekova YuL, Belenkov YuN et al. Clinical Guidelines. Chronic heart failure (CHF) on behalf of Society of Heart Failure Specialists, Russian Cardiac Society. Heart Failure Journal. 2017: 18 (1): 3–40. DOI: 10.18087/rhfj.2017.1.2346.
2. Baranov AA, Namazova-Baranova LS, Basargina EN, Belozerov YM, Degtyareva EA, Balykova LA i dr. Federalnii klinicheskie recomendacii po okazaniu medicinskoi pomoschi detyam s hronicheskoi serdechnoi nedostatochnostiu. 2015: 1–20.
3. Dipchand AI, Rossano JW, Edwards LB, Kucheryavaya AY, Benden C, Goldfab S et al. Yusen and Josef Stehlik; for the International Society for Heart and Lung Transplantation – The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Offi cial Pediatric Heart Transplantation Report – 2015; Focus Theme: Early Graft Failure. The Journal of Heart and Lung Transplantation. 2015; 1233: 1234–1243. DOI:10.1016/j.healun.2015.08.002.
4. Schweiger M, Stiasny B, Dave H, Cavigelli-Brunner A, Balmer C, Kretschmar O et al. Pediatric heart transplantation. Journal of Thoracic Disease. 2015; 7 (3): 552– 559. DOI:10.3978/j.ssn.2072-1439.2015.01.38.
5. The Registry of the International Society for Heart and Lung Transplantation 2016. The Journal of Heart and Lung Transplantation. 2016; 35 (10): 1149–1205.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献